Compare Mesoblast Limited (MESO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Plby Group Inc — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while Plby Group Inc trades at $0.97 (market cap $118.21M). The key difference: Mesoblast Limited is far larger — about 14.8× Plby Group Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Plby Group Inc for 24 Days on average.
| MESO | PLBY | |
|---|---|---|
Market Cap | $1.75B | $118.21M |
Volume | 239,027 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $2.71 |
52-Week Low | $13.19 | $0.99 |
Typical Hold Time | 14 Days | 24 Days |
Enterprise Value | $1.83B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
PLBY trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $12.67 million in 2025, though revenue grew to $120.93 million and the net loss narrowed significantly from prior years. Recent news highlights leadership appointments aimed at driving brand growth. The stock has a high P/E ratio of 49.34 but a reasonable P/S of 0.87, and analyst consensus is strongly bullish with 75% buy ratings.
The outlook is mixed: improving profitability trends and positive analyst sentiment offer potential upside, but high debt levels, negative shareholder equity, and bearish technicals pose significant risks. Investors should weigh the company's growth initiatives against its financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
